Journal article
Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery
Journal of controlled release, Vol.143(1), pp.38-44
2010
PMID: 20060024
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
An echogenic, intravenous drug delivery platform is proposed in which an encapsulated chemotherapeutic can travel to a desired location and drug delivery can be triggered using external, focused ultrasound at the area of interest. Three methods of loading poly(lactic acid) (PLA) shelled ultrasound contrast agents (UCA) with doxorubicin are presented. Effects on encapsulation efficiency,
in vitro enhancement, stability, particle size, morphology and release during UCA rupture are compared by loading method and drug concentration. An agent containing doxorubicin within the shell was selected as an ideal candidate for future hepatocellular carcinoma studies. The agent achieved a maximal drug load of 6.2
mg Dox/g PLA with an encapsulation efficiency of 20.5%, showed a smooth surface morphology and tight size distribution (poly dispersity index
=
0.309) with a peak size of 1865
nm. Acoustically, the agent provided 19
dB of enhancement
in vitro at a dosage of 10
µg/ml, with a half life of over 15
min.
In vivo, the agent provided ultrasound enhancement of 13.4
±
1.6
dB within the ascending aorta of New Zealand rabbits at a dose of 0.15
ml/kg. While the drug-incorporated agent is thought to be well suited for future drug delivery experiments, this study has shown that agent properties can be tailored for specific applications based on choice of drug loading method.
Drug loaded, echogenic ultrasound contrast agents have been developed and optimized. Doxorubicin was successfully loaded onto poly-L-lactide capsules with preservation of their echogenicity, enabling monitored delivery of chemotherapeutics to tumors.
[Display omitted]
Metrics
6 Record Views
Details
- Title
- Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery
- Creators
- J.R Eisenbrey - School of Biomedical Engineering, Science and Health Systems, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USAO. Mualem Burstein - School of Biomedical Engineering, Science and Health Systems, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USAR Kambhampati - School of Biomedical Engineering, Science and Health Systems, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USAF Forsberg - Department of Radiology, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107, USAJ.-B Liu - Department of Radiology, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107, USAM.A Wheatley - School of Biomedical Engineering, Science and Health Systems, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USA
- Publication Details
- Journal of controlled release, Vol.143(1), pp.38-44
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems
- Identifiers
- 991014878326804721
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Chemistry, Multidisciplinary
- Pharmacology & Pharmacy